. Author manuscript; available in PMC: 2011 Mar 1.

Published in final edited form as: Clin Cancer Res. 2010 Feb 16;16(5):1642–1651. doi: 10.1158/1078-0432.CCR-09-2701

Table 2.

Clinical characteristics of patients evaluated for T cell response to HY epitopes.

	FM group n=28	MM group n=22	P value
Age (median)	48 (19-64)	52 (19-63)	0.76
Indication for HSCT
Leukemia/ MDS	17/28 (60%)	12/22 (55%)	0.71
CLL / NHL / HD	10/28 (36%)	8/22 (36%)
Other (MM, SAA, CMML)	1/28 (4%)	2/22 (9%)
Conditioning Regimen
Myeloablative	10/28 (36%)	9/22 (40%)	0.77
Non-myeloablative	18/28 (64%)	13/22 (60%)
Stem Cell Source
Mobilized peripheral blood	26/28 (93%)	20/22 (91%)	1
Bone marrow	2/28 (7%)	2/22 (9%)
Donor Source: HLA-identical
Unrelated donors	9/28 (32%)	13/22 (59%)	0.09
Related donors	19/28 (68%)	9/22 (41%)
Acute GVHD (grade 2-4)	10/28(36)	1/22(5)	0.01
Chronic GVHD	28/28	18/22	0.06
Limited	8/28 (29%)	6/22 (27%)
Extensive	20/28 (71%)	12/22 (55%)
Date of Sample (median and range)
Days post- transplant	855 (200-2531)	609 (189-2407)	0.14

FM: male patients with female donors. MM: male patients with male donors. MDS: myelodysplastic syndrome, CLL: chronic lymphocytic leukemia, NHL: non Hodgkin lymphoma, HD: Hodgkin's disease, MM: multiple myeloma, SAA: severe aplastic anemia, CMML: chronic myelo-monocytic leukemia.